Skip to main content

Table 3 Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*

From: Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

   HR (95% CI) P
Anthracycline-treatment TIMP-1 low vs. all untreated 0.71 (0.42-1.19) 0.19
  TIMP-1 high vs. all untreated 0.97 (0.60-1.57) 0.90
CMF-treatment TIMP-1 low vs. all untreated 0.48 (0.33-0.69) <0.001
  TIMP-1 high vs. all untreated 0.57 (0.41-0.81) 0.001
Age 41-55 years vs. ≤ 40 years 0.63 (0.49-0.81) <0.001
Tumor size Stage 2 (> 2 cm) vs. stage 1 (≤ 2 cm) 1.80 (1.33-2.45) <0.001
  Stage 3 (>5 cm or chest wall/skin involvement) vs. stage 1 (≤ 2 cm) 1.86 (1.26-2.74)  
Grade Unknown vs. poor 0.83 (0.61-1.11) 0.08
  Well/moderate vs. poor 0.69 (0.49-0.98)  
  1. * Analyses stratified for hormone receptor status, nodal status and RT on the axilla. All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.